Targeting the dark side of the human genome—non-coding regulatory elements—to treat diseases

TargetNCREs aims to harness therapeutic potential of non-coding regulatory elements through innovative high-throughput screening, validating targets for commercial applications and market development.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

The 98% of the human genome, sometimes referred to as the dark side of the human genome, contains many non-coding regulatory elements (NCREs). These elements control the combinational expression of the limited number of genes (only 2% of the genome) to form diverse cell types and tissues of a complex human body, all from the identical copy of the genome.

Genetic Variants and Therapeutic Targets

Most genetic variants and mutations also lie in NCREs. However, the number of NCREs as potential therapeutic targets remains very limited.

Project Overview

In TargetNCREs, two novel and unique high-throughput screening systems further developed within the ECR starting grant (Silencer) will be exploited for their innovation and commercial potential to harness the therapeutic values of NCREs.

Objectives

We aim to:

  1. Test and validate previously identified top hits in vivo.
  2. Carry out pilot research to show the technologies to be effective and appropriate for commercial applications.
  3. Clarify the IPR protection strategy.
  4. Engage partners and stakeholders to focus on potential pipelines.
  5. Perform a market search for future business development.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-5-2024
Einddatum31-10-2025
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • ACADEMISCH ZIEKENHUIS LEIDENpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Profile nucleases and Repurpose Off-Targets to Expand Gene Editing

The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.

€ 1.141.779
ERC Consolid...

Targeting long non-coding RNAs for novel treatment strategies in vascular diseases

This project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes.

€ 1.999.495
ERC Starting...

Genetically anchored drug target discovery for neglected diseases

GenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases.

€ 1.498.089
ERC Consolid...

In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases

This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.

€ 2.249.895
ERC Proof of...

Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

€ 4.406.097
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
EIC Transition

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

€ 2.498.963
EIC Accelerator

A novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic diseases

eVai is a SaaS platform that enhances genetic variant interpretation, enabling accurate and rapid identification of pathogenic variants to improve diagnostic yields for genetic diseases.

€ 1.682.537